Associations - Tukysa (tucatinib)

HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + tucatinib Sensitive: A1 - Approval trastuzumab + tucatinib Sensitive : A1	trastuzumab + tucatinib Sensitive: A1 - Approval trastuzumab + tucatinib Sensitive : A1
RAS wild-type + HER-2 positive	Colorectal Cancer	RAS wild-type + HER-2 positive	Colorectal Cancer	trastuzumab + tucatinib Sensitive: A1 - Approval trastuzumab + tucatinib Sensitive : A1	trastuzumab + tucatinib Sensitive: A1 - Approval trastuzumab + tucatinib Sensitive : A1
HER-2 amplification + RAS wild-type + BRAF wild-type	Colon Cancer	HER-2 amplification + RAS wild-type + BRAF wild-type	Colon Cancer	trastuzumab + tucatinib Sensitive: A2 - Guideline trastuzumab + tucatinib Sensitive : A2	trastuzumab + tucatinib Sensitive: A2 - Guideline trastuzumab + tucatinib Sensitive : A2
HER-2 amplification + RAS wild-type + BRAF wild-type	Rectal Cancer	HER-2 amplification + RAS wild-type + BRAF wild-type	Rectal Cancer	trastuzumab + tucatinib Sensitive: A2 - Guideline trastuzumab + tucatinib Sensitive : A2	trastuzumab + tucatinib Sensitive: A2 - Guideline trastuzumab + tucatinib Sensitive : A2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	tucatinib Sensitive: B - Late Trials tucatinib Sensitive : B	tucatinib Sensitive: B - Late Trials tucatinib Sensitive : B
HER-2 positive	Colorectal Cancer	HER-2 positive	Colorectal Cancer	trastuzumab + tucatinib Sensitive: B - Late Trials trastuzumab + tucatinib Sensitive : B	trastuzumab + tucatinib Sensitive: B - Late Trials trastuzumab + tucatinib Sensitive : B
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	ado-trastuzumab emtansine + tucatinib Sensitive: B - Late Trials ado-trastuzumab emtansine + tucatinib Sensitive : B	ado-trastuzumab emtansine + tucatinib Sensitive: B - Late Trials ado-trastuzumab emtansine + tucatinib Sensitive : B
HER-2 positive	Biliary Tract Cancer	HER-2 positive	Biliary Tract Cancer	trastuzumab + tucatinib Sensitive: C1 - Off-label trastuzumab + tucatinib Sensitive : C1	trastuzumab + tucatinib Sensitive: C1 - Off-label trastuzumab + tucatinib Sensitive : C1
HER-2 amplification	Breast Cancer	HER-2 amplification	Breast Cancer	tucatinib Sensitive: C2 – Inclusion Criteria tucatinib Sensitive : C2	tucatinib Sensitive: C2 – Inclusion Criteria tucatinib Sensitive : C2
HER-2 amplification	Breast Cancer	HER-2 amplification	Breast Cancer	trastuzumab + tucatinib Sensitive: C2 – Inclusion Criteria trastuzumab + tucatinib Sensitive : C2	trastuzumab + tucatinib Sensitive: C2 – Inclusion Criteria trastuzumab + tucatinib Sensitive : C2
HER-2 expression	Colorectal Cancer	HER-2 expression	Colorectal Cancer	trastuzumab + tucatinib Sensitive: C3 – Early Trials trastuzumab + tucatinib Sensitive : C3	trastuzumab + tucatinib Sensitive: C3 – Early Trials trastuzumab + tucatinib Sensitive : C3
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	palbociclib + tucatinib Sensitive: C3 – Early Trials palbociclib + tucatinib Sensitive : C3	palbociclib + tucatinib Sensitive: C3 – Early Trials palbociclib + tucatinib Sensitive : C3
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	trastuzumab + tucatinib Sensitive: C3 – Early Trials trastuzumab + tucatinib Sensitive : C3	trastuzumab + tucatinib Sensitive: C3 – Early Trials trastuzumab + tucatinib Sensitive : C3
HER-2 positive	Gastroesophageal Cancer	HER-2 positive	Gastroesophageal Cancer	trastuzumab + ramucirumab + tucatinib Sensitive: C3 – Early Trials trastuzumab + ramucirumab + tucatinib Sensitive : C3	trastuzumab + ramucirumab + tucatinib Sensitive: C3 – Early Trials trastuzumab + ramucirumab + tucatinib Sensitive : C3
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	palbociclib + tucatinib Sensitive: C3 – Early Trials palbociclib + tucatinib Sensitive : C3	palbociclib + tucatinib Sensitive: C3 – Early Trials palbociclib + tucatinib Sensitive : C3
HER-2 mutation	Estrogen Receptor Positive Breast Cancer	HER-2 mutation	Estrogen Receptor Positive Breast Cancer	tucatinib Sensitive: C4 – Case Studies tucatinib Sensitive : C4	tucatinib Sensitive: C4 – Case Studies tucatinib Sensitive : C4
HER-2 L755S	HER2 Positive Breast Cancer	HER-2 L755S	HER2 Positive Breast Cancer	tucatinib Resistant: D – Preclinical tucatinib Resistant : D	tucatinib Resistant: D – Preclinical tucatinib Resistant : D
HER-2 L755S	HER2 Positive Breast Cancer	HER-2 L755S	HER2 Positive Breast Cancer	trastuzumab + tucatinib Resistant: D – Preclinical trastuzumab + tucatinib Resistant : D	trastuzumab + tucatinib Resistant: D – Preclinical trastuzumab + tucatinib Resistant : D
HER-2 V777L	Gastric Cancer	HER-2 V777L	Gastric Cancer	tucatinib Sensitive: D – Preclinical tucatinib Sensitive : D	tucatinib Sensitive: D – Preclinical tucatinib Sensitive : D
HER-2 L755S	Gastric Cancer	HER-2 L755S	Gastric Cancer	tucatinib Sensitive: D – Preclinical tucatinib Sensitive : D	tucatinib Sensitive: D – Preclinical tucatinib Sensitive : D
HER-2 S310Y	Gastric Cancer	HER-2 S310Y	Gastric Cancer	trastuzumab + tucatinib Sensitive: D – Preclinical trastuzumab + tucatinib Sensitive : D	trastuzumab + tucatinib Sensitive: D – Preclinical trastuzumab + tucatinib Sensitive : D
HER-2 S310Y	Gastric Cancer	HER-2 S310Y	Gastric Cancer	tucatinib Sensitive: D – Preclinical tucatinib Sensitive : D	tucatinib Sensitive: D – Preclinical tucatinib Sensitive : D
HER-2 L755S	Colorectal Cancer	HER-2 L755S	Colorectal Cancer	tucatinib Sensitive: D – Preclinical tucatinib Sensitive : D	tucatinib Sensitive: D – Preclinical tucatinib Sensitive : D
HER-2 V777L	Colorectal Cancer	HER-2 V777L	Colorectal Cancer	trastuzumab + tucatinib Sensitive: D – Preclinical trastuzumab + tucatinib Sensitive : D	trastuzumab + tucatinib Sensitive: D – Preclinical trastuzumab + tucatinib Sensitive : D
HER-2 V777L	Colorectal Cancer	HER-2 V777L	Colorectal Cancer	tucatinib Sensitive: D – Preclinical tucatinib Sensitive : D	tucatinib Sensitive: D – Preclinical tucatinib Sensitive : D
HER-2 L755S	Non Small Cell Lung Cancer	HER-2 L755S	Non Small Cell Lung Cancer	tucatinib Sensitive: D – Preclinical tucatinib Sensitive : D	tucatinib Sensitive: D – Preclinical tucatinib Sensitive : D
HER-2 V777L	Non Small Cell Lung Cancer	HER-2 V777L	Non Small Cell Lung Cancer	tucatinib Sensitive: D – Preclinical tucatinib Sensitive : D	tucatinib Sensitive: D – Preclinical tucatinib Sensitive : D
HER-2 S310Y	Colorectal Cancer	HER-2 S310Y	Colorectal Cancer	trastuzumab + tucatinib Sensitive: D – Preclinical trastuzumab + tucatinib Sensitive : D	trastuzumab + tucatinib Sensitive: D – Preclinical trastuzumab + tucatinib Sensitive : D
HER-2 S310Y	Colorectal Cancer	HER-2 S310Y	Colorectal Cancer	tucatinib Sensitive: D – Preclinical tucatinib Sensitive : D	tucatinib Sensitive: D – Preclinical tucatinib Sensitive : D
HER-2 S310Y	Non Small Cell Lung Cancer	HER-2 S310Y	Non Small Cell Lung Cancer	trastuzumab + tucatinib Sensitive: D – Preclinical trastuzumab + tucatinib Sensitive : D	trastuzumab + tucatinib Sensitive: D – Preclinical trastuzumab + tucatinib Sensitive : D
HER-2 expression	Colorectal Cancer	HER-2 expression	Colorectal Cancer	tucatinib Sensitive: D – Preclinical tucatinib Sensitive : D	tucatinib Sensitive: D – Preclinical tucatinib Sensitive : D
HER-2 S310Y	Non Small Cell Lung Cancer	HER-2 S310Y	Non Small Cell Lung Cancer	tucatinib Sensitive: D – Preclinical tucatinib Sensitive : D	tucatinib Sensitive: D – Preclinical tucatinib Sensitive : D

Tukysa (tucatinib)

Associations
(39)

Associations
(39)

Tukysa (tucatinib)

Associations(39)

Associations(39)

Associations
(39)

Associations
(39)